Key facts
- Conceivable Life Sciences’s last known valuation is $145.0M (Aug 2025).
- It has raised $88.5M across 3 recorded rounds; the latest was Early Stage VC ($30.5M) in Aug 2025.
- Notable investors include ACME Capital, Advance Venture Partners, Muse Capital, Black Opal Ventures, Time BioVentures — 13 tracked in total.
- Conceivable Life Sciences has filed 4 Form Ds with the SEC since 2023, most recently Sep 2025 ($30.5M sold to 20 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Conceivable Life Sciences
Funding rounds
3 roundsAbout Conceivable Life Sciences
Developer of a fully automated AI-powered IVF lab designed to improve precision, quality, and scalability in fertility treatments. The company offers an integrated platform that handles all IVF lab functions, including sperm processing, egg preparation, and incubation, enabling individuals facing infertility to access consistent and safer fertility care.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2022
- Employees
- 48
- Website
- conceivable.life/
- Ownership
- Privately Held (backing)
Conceivable Life Sciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Conceivable Life Sciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Conceivable Life Sciences in its N-PORT filings yet. We sweep new filings monthly.